menu-hamburger-svgrepo-com

WEBINAR REPLAY

Webinar replay of HIV: Dual Treatment

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Presented by

:
:
DAYS
HRS
MINS

BOOKINGS

Cipla
Macro coronavirus(covid-19) cell delta plus variant. B.1.1.529,B.1640.1,deltacron,COVID 19 variant of SARS-CoV-2 in 2022.Mutated coronavirus SARS-CoV-2 flu disease pandemic,3D render illustration

In case you missed the live webinar, or you would like to watch it again, here is the link to the replay video: https://event.webinarjam.com/go/replay/516/kr4vrblmb8xix5t1  

To earn a CPD point from watching the replay, email john.woodford@newmedia.co.za to let him know that you have watched the webinar. 

The key points from this presentation are: 

Currently, the only two-drug option as treatment initiation is 3TC (or FTC) + DTG. 

This is non-inferior to three-drug regimens at least to three years. There is a similar safety profile and a small renal advantage. 

BUT, have to be careful in who you select for this regimen: 

  • Viral load must be <500,000 copies/mL. 
  • CD4 must be <200 cells/mm3. 
  • Can’t have hepatitis B or TB. 
  • Must be a true initiation (not re-initiation). 
  • Should ideally be a patient who you don’t have adherence concerns about. 

Patients on other first line therapies who are virally suppressed and have never had any virological failure could be shifted to:​ 

  • 3TC + DTG or ​ 
  • 3TC + RPV or ​ 
  • CAB + RPV.​ 
  • … if this makes sense from a cost or side-effect point of view.​ 

Be careful with: hepatitis B, TB, key drug-interactions with RPV, patient needs to be reliably adherent.​ 

 

Sign in to access full articles and earn your CPD points.

Clinical and CPD content is compiled by Key Opinion Leaders and our expert medical editors.

Already registered? Login here

Past webinars

Suggested clinical & CPD content

Related articles

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP
Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.